Tandem Diabetes Expands Tandem Mobi Insulin Delivery System to 12…

Event summary

Tandem Diabetes Care has launched its Tandem Mobi automated insulin delivery system in 12 international markets, including Belgium, Germany, and the UK.
The system features Control-IQ+ technology, which predicts glucose levels 30 minutes ahead and adjusts insulin delivery every 5 minutes.
Tandem Mobi is compatible with the Dexcom G7 continuous glucose monitoring system, with additional sensor integrations planned for 2027.
The company is taking orders and shipping to eligible customers in the new markets as of September 28, 2026.

The big picture

Tandem Diabetes Care's expansion of the Tandem Mobi system into 12 new international markets marks a significant step in its strategy to globalize its diabetes technology portfolio. The move aligns with broader industry trends toward automated insulin delivery systems, which aim to reduce the burden of diabetes management. The company's focus on durability, wearability, and advanced algorithmic control positions it competitively in a market increasingly dominated by technological innovation.

What we're watching

Market Penetration: Whether Tandem Diabetes can sustain the pace of international expansion and maintain commercial scale for Tandem Mobi pumps.
Technological Integration: The pace at which Tandem Diabetes integrates additional sensors, such as Abbott sensors, and expands Android compatibility.
Regulatory Compliance: How regulatory approvals in new markets will affect the timeline for further international rollouts.